 |
Vol.64 No.3 contents | Japanese/English |
 | Full Text of PDF (1764K) Article in Japanese |
- Case Report -
Two Cases of EGFR-mutated Non-small-cell Lung Cancer Treated with Erlotinib+Ramucirumab After Osimertinib-induced Lung Injury
Yuki Endo1, Koji Inoue2, Tomoya Katsuta2, Sayaka Tachibana2, Haruka Kondo2, Junya Nakamura2, Shohei Nozu2, Kento Aibara2, Norihiko Nakanishi2, Tomonori Moritaka21Clinical Training Center, 2Department of Respiratory Medicine, Ehime Prefectural Central Hospital, Japan
Background. There is no consensus regarding the use of EGFR tyrosine kinase inhibitors after osimertinib-induced lung injury. Case 1. A 63-year-old man was diagnosed with stage IVB non-small-cell lung cancer with multiple brain metastases (EGFR del19 mutation-positive), and treatment with osimertinib was started and temporarily achieved a partial response. However, the treatment was discontinued because of drug-induced lung injury. The patient was then treated with multiple chemotherapies with cytotoxic agents, but his multiple brain metastases progressed, so we selected treatment with erlotinib+ramucirumab. Both the trunk and brain lesions showed a partial response, and he was able to continue treatment without recurrence of lung injury until the progression of his brain metastasis seven months later. Case 2. A 77-year-old woman was treated with osimertinib after being diagnosed with stage IVA non-small-cell lung carcinoma (EGFR/L858R mutation-positive). However, the treatment was discontinued after four weeks due to lung injury. She was then treated with erlotinib+ramucirumab after γ-knife therapy. Five months later, she was still able to receive her treatment with no recurrence of lung injury. Conclusion. We herein report two patients with EGFR mutation-positive non-small-cell lung cancer who developed lung injury after osimertinib treatment and received erlotinib+ramucirumab to control brain metastases.
key words: Osimertinib-induced lung injury, Brain metastases, Erlotinib+ramucirumab, Anti-VEGF anti-body
Received: January 28, 2024
Accepted: March 6, 2024
JJLC 64 (3): 186-192, 2024
